试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-27
Randomized Evaluation of Beta Blocker and ACEI/ARB Treatment in MINOCA Patients - MINOCA-BAT
编号:NCT03686696登记状态:提前终止企业 / 申办者:Uppsala University
药物 / 成分:Beta blocker、ACEI、ARB
登记的停止原因(原文):Low inclusion rate.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-24
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
编号:NCT01215136登记状态:提前终止企业 / 申办者:Matthew Galsky
药物 / 成分:Everolimus、Everolimus、Paclitaxel
登记的停止原因(原文):Lack of Accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-24
Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma
编号:NCT02168270登记状态:提前终止企业 / 申办者:University of Nebraska
药物 / 成分:ascorbic acid、temozolomide、quality-of-life assessment、laboratory biomarker analysis
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-24
A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
编号:NCT03496623登记状态:提前终止企业 / 申办者:United Therapeutics
药物 / 成分:Inhaled treprostinil solution、Placebo solution
登记的停止原因(原文):Sponsor's decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-24
OH2 Oncolytic Viral Therapy in Pancreatic Cancer
编号:NCT04637698登记状态:提前终止企业 / 申办者:Binhui Biopharmaceutical Co., Ltd.
药物 / 成分:OH2 injection
登记的停止原因(原文):Strategy adjustment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-24
A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)
编号:NCT04948554登记状态:提前终止企业 / 申办者:Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
药物 / 成分:MK-2225、Placebo
登记的停止原因(原文):Business Reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-22
Dexamethasone Versus Depo Medrol in Lumbar Epidurals
编号:NCT01397552登记状态:提前终止企业 / 申办者:State University of New York - Upstate Medical University
药物 / 成分:Dexamethasone、methylprednisolone acetate
登记的停止原因(原文):Low enrollment, too many subjects getting second injection
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-22
A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients
编号:NCT02285543登记状态:提前终止企业 / 申办者:Shanghai Jiao Tong University School of Medicine
药物 / 成分:TPF induction chemotherapy、surgery、radiotherapy
登记的停止原因(原文):No new participants could be enrolled.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-22
M3541 in Combination With Radiotherapy in Solid Tumors
编号:NCT03225105登记状态:提前终止企业 / 申办者:EMD Serono Research & Development Institute, Inc.
药物 / 成分:M3541、Palliative Radiotherapy (RT)
登记的停止原因(原文):The study was terminated early per sponsor decision to halt further development of M3541 due to pharmaceutical and PK/pharmacodynamics properties that precluded further clinical development.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-22
Hypertrophic Scar Prevention by Novel Topical Gel Application
编号:NCT03403621登记状态:提前终止企业 / 申办者:Mayo Clinic
药物 / 成分:Pentamidine Isethionate、Placebo
登记的停止原因(原文):Funding changes.
查看官方原始记录 ↗